Precision Biologics' development of monoclonal antibodies against tumor-specific targets in cancer to be focus of presentation at the Festival of Biologics USA, San Diego Convention Center, San Diego, CA, March 4-5, 2026
PR Newswire —
BETHESDA, Md., March 2, 2026 /PRNewswire/ -- Precision Biologics, Inc. CEO Philip M. Arlen, MD, discusses discovery and development of tumor-specific monoclonal antibodies (mAb) in "Discovery and Development of Monoclonal Antibodies Targeting Tumor Specific Neoepitopes" at the Festival of...